Clinical Cancer Research, Vol 4, Issue 1 61-68, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study

SC Srivastava, HL Atkins, GT Krishnamurthy, I Zanzi, EB Silberstein, G Meinken, LF Mausner, F Swailem, T D'Alessandro, CJ Cabahug, Y Lau, T Park and S Madajewicz
Medical Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA.

The physical characteristics of Sn-117m combined with the biodistribution of the compound tin-117m (Stannic, 4+) diethylenetriaminepentaacetic acid (Sn-117m DTPA) suggest that it should be an excellent agent for the palliation of pain from bony metastases. Prior work has established the dosimetry and the safety for the material in human beings. The presence of low-energy conversion electrons should result in the relative sparing of the bone marrow while delivering a high radiation dose to sites of bony metastatic disease. Forty-seven patients with painful bone metastases from various malignancies were treated with Sn-117m DTPA. The patients were assigned to five different dose levels ranging from 2.64 to 10.58 MBq (71-286 microCi) per kg of body weight. Follow-up included review of pain diaries, performance scores, analgesic requirements, blood chemistries, and hematological assessment. Three patients received a second treatment. There was an overall response rate for relief of pain of 75% (range, 60-83%) in the 40 treatments that could be evaluated. No correlation was apparent in this limited series between response rate and the five dose levels used. The relief was complete in 12 patients (30%). The time to onset of pain relief was 19 +/- 15 days with doses < or = 5.29 MBq/kg and 5 +/- 3 days with doses > or = 6.61 MBq/kg. Myelotoxicity was minimal, with only one patient having a marginal grade 3 WBC toxicity. On the basis of our data, Sn-117m DTPA should be an effective and safe radiopharmaceutical for palliation of painful bony metastases. A large-scale trial is warranted to evaluate it in comparison to other similar agents.

This article has been cited by other articles:

				S. Nilsson, R. H. Larsen, S. D. Fossa, L. Balteskard, K. W. Borch, J.-E. Westlin, G. Salberg, and O. S. Bruland First Clinical Experience with {alpha}-Emitting Radium-223 in the Treatment of Skeletal Metastases Clin. Cancer Res., June 15, 2005; 11(12): 4451 - 4459. [Abstract] [Full Text] [PDF]

				V. J. Lewington Bone-Seeking Radionuclides For Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 38S - 47S. [Abstract] [Full Text] [PDF]

				N. Pandit-Taskar, M. Batraki, and C. R. Divgi Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases J. Nucl. Med., August 1, 2004; 45(8): 1358 - 1365. [Abstract] [Full Text] [PDF]

				H. Smith, A. Navani, and S. M. Fishman Radiopharmaceuticals for palliation of painful osseous metastases American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313. [Abstract] [PDF]

				G. Henriksen, K. Breistol, O. S. Bruland, O. Fodstad, and R. H. Larsen Significant Antitumor Effect from Bone-seeking, {alpha}-Particle-emitting 223Ra Demonstrated in an Experimental Skeletal Metastases Model Cancer Res., June 1, 2002; 62(11): 3120 - 3125. [Abstract] [Full Text] [PDF]

				A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]

				A. Bishayee, D. V. Rao, S. C. Srivastava, L. G. Bouchet, W. E. Bolch, and R. W. Howell Marrow-Sparing Effects of 117mSn(4+)Diethylenetriaminepentaacetic Acid for Radionuclide Therapy of Bone Cancer J. Nucl. Med., December 1, 2000; 41(12): 2043 - 2050. [Abstract] [Full Text] [PDF]